Test Your Skills: 1L HR Pos HER2 Pos mBC

CE / CME

Management of a Patient With Newly Diagnosed HR+/HER2+ mBC on Medication for Comorbidities

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.50 Medical Knowledge MOC point

Released: April 21, 2025

Expiration: October 20, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

Which of the following findings was reported from the randomized, open-label phase III PATINA study evaluating the efficacy and safety of palbociclib combined with standard-of-care anti-HER2 therapy plus endocrine therapy (ET) vs anti-HER2 therapy plus ET alone as maintenance therapy after induction treatment in patients with hormone receptor (HR)–positive/HER2-positive metastatic breast cancer (mBC)?